Last reviewed · How we verify
Inmazeb (ODESIVIMAB)
Inmazeb works by binding to the Ebola virus, preventing it from interacting with host cells.
Inmazeb (odesivimab) is a monoclonal antibody developed by Regeneron Pharmaceuticals, targeting the low affinity immunoglobulin gamma Fc region receptor III-A. It is used to treat Ebola virus disease and was FDA-approved in 2020. Inmazeb is a proprietary medication, and its commercial status is patented. Key safety considerations include its potential to cause infusion-related reactions and hypersensitivity. As a monoclonal antibody, Inmazeb works by binding to the Ebola virus, preventing it from interacting with host cells.
At a glance
| Generic name | ODESIVIMAB |
|---|---|
| Sponsor | Regeneron |
| Target | Low affinity immunoglobulin gamma Fc region receptor III-A |
| Modality | Monoclonal antibody |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 2020 |
| Annual revenue | 76 |
Mechanism of action
INMAZEB is an antiviral drug combination of three recombinant human IgG1 monoclonal antibodies (atoltivimab, maftivimab, and odesivimab) that inhibit Zaire ebolavirus [see Microbiology (12.4) ].
Approved indications
- Ebola virus disease
Common side effects
- Pyrexia
- Chills
- Tachycardia
- Tachypnea
- Vomiting
- Hypotension
- Diarrhea
- Hypoxia
- Sodium, high
- Sodium, low
- Potassium, high
- Potassium, low
Key clinical trials
- EBOla Post-Exposure Prophylaxis (PHASE3)
- Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers (PHASE2)
- R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of Ebola Virus Disease
- Investigational Therapeutics for the Treatment of People With Ebola Virus Disease (PHASE2,PHASE3)
- Study of Safety, Tolerability, and Pharmacokinetics of REGN3470-3471-3479 in Healthy Adult Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Inmazeb CI brief — competitive landscape report
- Inmazeb updates RSS · CI watch RSS
- Regeneron portfolio CI